Promoting freedom, innovation, and growth

Connect with IPI

Receive news, research, and updates

Intellectual PropertyIntellectual Property RSS Feed

Economic growth begins with ideas, innovation and creativity. Since the signing of the Constitution, the U.S. has protected the fruits of creativity and innovation through intellectual property protection, primarily expressed as patents, trademarks, copyright and trade secrets.

As our economy has become even more dependent on innovation, intellectual property issues have been pushed to the forefront. The clashes have led some to question the value and even the legitimacy of IP protection. While some of these attacks come from the libertarian perspective, most originate from the same naïve socialist impulses that so demonstrably failed in the realm of real property—but somehow are seen as thoughtful with respect to IP.

IPI believes that creators have the right to own and control the fruits of their creativity, and that the IP system has done an admirable job of not only incentivizing innovation, but also making creative products and services available to the public and transferring technology to the developing world.

December 7, 2015

Patent Trolls: Fraudsters Make Easy Money Due To American Law


The need for patent reform is not a new issue, but a recent ruling provides a perfect example of all that is wrong with our current system. 

December 4, 2015

Stolen Notes

For the Loyola community, illegal downloading is a problem among students and faculty alike. About $12.5 billion is lost in the U.S. economy each year because of music piracy, according to a study by the Institute for Policy Innovation. 

November 5, 2015

Lower Drug Prices by Streamlining Approval Process, Delaying IP Clock


A new publication shows how competition, streamlining the drug-approval process, and leveraging the power of intellectual property protections are the keys to unlock lower prices for consumers. 

November 4, 2015

Explaining the High Cost of Prescription Drugs


Many brand name prescription drugs are expensive, and there are reasons for that. But most of the proposed political "fixes" would only make them more expensive or ensure they never reach the market. The better solution to controlling prices is to reduce onerous regulations an expand competition.

October 12, 2015

Flawed By Design


The next juicy target for “patent trolls” is ripening. Design patents have become increasingly attractive as a new target.

August 3, 2015

The Three Dumbest "Conservative" Objections to Patent Reform

One argument basically is: Obama supports patent reform, therefore it must be a liberal idea. But patent reform enjoys a long tradition of intellectual support from a wide range of right-leaning think tanks and advocacy groups, including IPI.

July 20, 2015

Coalition Letter Supporting Strong Protections for All Types of IP

A coalition of 85 organizations from 51 countries calls for global policymakers to bear serious consideration to the integral role that the IP rights of innovators, creators and entrepreneurs plays in economic, technological and cultural advancement.

July 16, 2015

Why No One Will Reform Washington

The R&D tax credit has been a “temporary” provision in the tax code since 1981. Each time the credit is about to expire, Congress rallies support to renew the tax break from those who benefit from it. As the libertarian IPI puts it, “this cycle has repeated itself for years ... Congress essentially uses this cycle to raise money for re-election, promising the industry more predictability the next time around.”

April 17, 2015

Drug R&D Costs: $1.7 Billion and Rising


The significant costs of developing new, life-saving drugs and treatments has reached over $1.7 billion per drug over a span of 10-12 years, due to the growing complexity of drugs, bureaucratic red tape and the short length of a drug’s patent life.

April 16, 2015

The High Cost of Inventing New Drugs--And of Not Inventing Them


The cost of developing new prescription drugs is very expensive—a process made even more expensive than it has to be because of excessive government restrictions and limited patent life. However, not developing new drugs can also be expensive, both in financial and human costs.

 

Total Records: 150

 

 

  • TaxBytes-New

Copyright Institute for Policy Innovation 2017. All Rights Reserved Privacy Policy Contact IPI.

e-resources e-resources